CDKN2A and exocrine pancreatic carcinoma: Given that melanoma and pancreatic carcinoma share some common genetic and signaling features, including loss of p16Ink4a, predisposing to melanoma and pancreatic carcinoma, we evaluated the effect of tris DBA treatment in pancreatic carcinoma.